Zhejiang Xianju Pharmaceutical Co., Ltd. (SZSE: 002332)
Health Care · Pharmaceuticals · CN
CN¥8.44
-0.59% today · -26.1% 1Y
Zhejiang Xianju Pharmaceutical Co., Ltd. (SZSE: 002332) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.24B and employs 3,209 people.
Over the last twelve months the share price has lost 26.1%, trading between 7.92 and 11.65.
Tweenvest scores Zhejiang Xianju Pharmaceutical Co., Ltd. across four factors: quality 73/100, value 50/100, growth 26/100, dividend 68/100. Its strongest factor is quality.
002332 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.24B
- Revenue (TTM)
- $531.96M
- P/E
- 21.11
- EPS
- 0.40
- Dividend yield
- 4.74%
- Beta (5Y)
- 0.18
- 52-week high
- CN¥11.65
- 52-week low
- CN¥7.92
- Avg volume (3M)
- —
- Shares outstanding
- 989.20M
- Employees
- 3,209
- Next earnings
- —
About Zhejiang Xianju Pharmaceutical Co., Ltd.
Zhejiang Xianju Pharmaceutical Co.,Ltd. is a global enterprise specializing in the production and distribution of steroidal and hormonal pharmaceutical products. Its offerings span active pharmaceutical ingredients (APIs), specifically steroid-based medications and both male and female hormones, alongside various chemical intermediates. The company also provides a comprehensive selection of finished dosage forms, including tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-for-injection preparations. Established in 1972, Zhejiang Xianju Pharmaceutical Co.,Ltd. operates from its headquarters in Xianju, China.
- ISIN
- CNE100000K64
- Founded
- 1972
- Listed since
- Jan 12, 2010
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.81 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.49 | +0.46% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.48 | -0.05% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.90 | -1.52% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.80 | -1.31% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.